Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.

Yajing Wu,Vivek Verma,Carl M Gay,Yujia Chen,Fei Liang,Qiang Lin,Jianing Wang,Wei Zhang,Zhouguang Hui,Min Zhao,Jun Wang,Joe Y Chang

Cancer（2023）

引用 0|浏览24

暂无评分

摘要

This meta-analysis of 66 studies showed that neoadjuvant immunotherapy for advanced resectable non-small cell lung cancer is safe and efficacious. Compared with chemotherapy alone, chemoimmunotherapy improved pathologic response rates and survival, particularly for patients who had tumors that expressed programmed cell death ligand-1, without increasing toxicities.

查看译文

关键词

immunotherapy,neoadjuvant,non-small cell lung cancer,pathologic response,survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要